安眠药:安眠药的新产品?

IF 2.6 4区 医学 Q3 NEUROSCIENCES
Acta Neuropsychiatrica Pub Date : 2015-02-01 Epub Date: 2014-11-14 DOI:10.1017/neu.2014.31
Abhishek Reddy, Sowmya C Puvvada, Satyanarayana Kommisetti, Rif S El-Mallakh, Steven Lippmann
{"title":"安眠药:安眠药的新产品?","authors":"Abhishek Reddy,&nbsp;Sowmya C Puvvada,&nbsp;Satyanarayana Kommisetti,&nbsp;Rif S El-Mallakh,&nbsp;Steven Lippmann","doi":"10.1017/neu.2014.31","DOIUrl":null,"url":null,"abstract":"<p><p>Orexin, also called hypocretin, is a neuropeptide that acts on central nervous system receptors to promote arousal. Suvorexant, its receptor antagonist, generates interest as a medication to treat insomnia. Suvorexant helps in decreasing wakefulness by counteracting orexin activity. Its low side effect potential may offer considerable benefit. Compared with other sleep aids, diminished drowsiness and less cognitive dysfunction is an advantage. Now approved for clinical use, an apparent lack of rebound insomnia or drug dependence potential might make suvorexant a good choice pharmacotherapy for patients with insomnia. </p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/neu.2014.31","citationCount":"2","resultStr":"{\"title\":\"Suvorexant: something new for sleep?\",\"authors\":\"Abhishek Reddy,&nbsp;Sowmya C Puvvada,&nbsp;Satyanarayana Kommisetti,&nbsp;Rif S El-Mallakh,&nbsp;Steven Lippmann\",\"doi\":\"10.1017/neu.2014.31\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Orexin, also called hypocretin, is a neuropeptide that acts on central nervous system receptors to promote arousal. Suvorexant, its receptor antagonist, generates interest as a medication to treat insomnia. Suvorexant helps in decreasing wakefulness by counteracting orexin activity. Its low side effect potential may offer considerable benefit. Compared with other sleep aids, diminished drowsiness and less cognitive dysfunction is an advantage. Now approved for clinical use, an apparent lack of rebound insomnia or drug dependence potential might make suvorexant a good choice pharmacotherapy for patients with insomnia. </p>\",\"PeriodicalId\":48964,\"journal\":{\"name\":\"Acta Neuropsychiatrica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2015-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1017/neu.2014.31\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Neuropsychiatrica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1017/neu.2014.31\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2014/11/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Neuropsychiatrica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/neu.2014.31","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/11/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 2

摘要

食欲素,也叫下丘脑分泌素,是一种神经肽,作用于中枢神经系统受体,促进觉醒。它的受体拮抗剂Suvorexant作为一种治疗失眠的药物引起了人们的兴趣。Suvorexant通过对抗食欲素活动来帮助减少清醒。其潜在的低副作用可能会带来相当大的好处。与其他助眠剂相比,减少困倦和减少认知功能障碍是一种优势。现在已被批准用于临床,明显缺乏反弹性失眠或药物依赖潜力可能使suvorexant成为失眠患者的良好选择药物治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Suvorexant: something new for sleep?

Orexin, also called hypocretin, is a neuropeptide that acts on central nervous system receptors to promote arousal. Suvorexant, its receptor antagonist, generates interest as a medication to treat insomnia. Suvorexant helps in decreasing wakefulness by counteracting orexin activity. Its low side effect potential may offer considerable benefit. Compared with other sleep aids, diminished drowsiness and less cognitive dysfunction is an advantage. Now approved for clinical use, an apparent lack of rebound insomnia or drug dependence potential might make suvorexant a good choice pharmacotherapy for patients with insomnia.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Neuropsychiatrica
Acta Neuropsychiatrica NEUROSCIENCES-PSYCHIATRY
自引率
5.30%
发文量
30
期刊介绍: Acta Neuropsychiatrica is an international journal focussing on translational neuropsychiatry. It publishes high-quality original research papers and reviews. The Journal''s scope specifically highlights the pathway from discovery to clinical applications, healthcare and global health that can be viewed broadly as the spectrum of work that marks the pathway from discovery to global health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信